학술논문
Anti GD2-antibody with GM-CSF, interleukin-2, and isotrectinoin for neuroblastoma
Document Type
Clinical report
Author
Yu, Alice L.; Gilman, Andrew L.; Ozkaynak, M. Ferzi; London, Wendy B.; Kreissman, Susan G.; Chen, Helen X.; Smith, Malcolm; Anderson, Barry; Villablanca. Judith G.; Matthay, Katherine K.; Hiro Shmiada; Grupp, Stephan A.; Seeger, Robert; Reynolds, C. Patrick; Buxton, Allan; Reisfield, Ralph A.; Gillies, Steven D.; Cohn, Susan L.; Maris, John M.; Sondel, Paul M.
Source
The New England Journal of Medicine. Sept 30, 2010, Vol. 363 Issue 14, p1234, 11 p.
Subject
Language
English
ISSN
0028-4793
Abstract
A study was conducted to evaluate whether adding ch14.18, a monoclonal anti GD2-antibody with GM-CSF and interleukin-2, and isotrectinoin would have positive outcomes in the case of patients with neuroblastoma. Results indicated that the combination os such therapies resulted in better outcomes in the case of such patients.